Pharmaceuticals News and Research

RSS

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

Cumberland Pharmaceuticals Inc. today announced an expansion of its pipeline with a new Phase II development program. The Company has initiated the clinical development of Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease (AERD).

11 Feb 2015

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

ChromaDex Corp. announced today that the initial results of the first human clinical study for the company's NIAGEN nicotinamide riboside (NR) has met its primary endpoint.

11 Feb 2015

IU School of Medicine launches Industry Collaboration Portal

The Indiana University School of Medicine has launched an initiative and accompanying web site to encourage more collaboration between private industry and researchers at the medical school.

11 Feb 2015

UM one step closer to developing potential drug for treating brain cancer

Promentis Pharmaceuticals, Inc. recently announced it will enter an exclusive agreement with UM to commercialize a discovery made by a team of UM faculty scientists that has the potential to treat brain cancer and possibly other disorders of the central nervous system.

11 Feb 2015

SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies

The SPR Center of Excellence is based in Dijon, France. Inventiva’s existing pharmaceutical discovery platform will now include SensiQ SPR technology, which strengthens Inventiva’s current service offering.

10 Feb 2015

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

Isis Pharmaceuticals, Inc. announced today it has earned a $5 million milestone payment from Biogen Idec associated with the validation of an undisclosed target to treat a neurological disorder under its broad strategic collaboration with Biogen Idec to develop drugs to treat patients with neurological disorders.

10 Feb 2015

University of Tokyo researchers reveal how TLR9 binds to pathogen DNA

University of Tokyo researchers have elucidated how Toll-like receptor 9 (TLR9) binds to pathogen DNA, activating the innate immune system. This discovery is vital for the design of new antiviral, antibacterial, allergy and other drugs targeting TLR9.

10 Feb 2015

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

A study led by researchers at the Institute for Molecular Medicine Finland FIMM and Faculty of Medicine, University of Helsinki and the Helsinki University Central Hospital Comprehensive Cancer Center, in close collaboration with researchers at Pfizer, has identified a previously unrecognized action of Pfizer's axitinib as a potent inhibitor of the dominant mutation that confers drug resistance to all well tolerated treatments in patients with certain types of leukemia.

10 Feb 2015

Researchers discover inherited genetic variations associated with treatment-related hearing loss

St. Jude Children's Research Hospital investigators have discovered inherited genetic variations that are associated with rapid hearing loss in young cancer patients treated with the drug cisplatin. The research appears in the current online issue of the scientific journal Nature Genetics.

10 Feb 2015

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers.

10 Feb 2015

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

Inspirion Delivery Technologies, LLC, a specialty pharmaceutical company focused solely on the development of Abuse-Deterrent Formulations (ADFs) of opioid products, together with its financial partner Trygg Pharma Group, announced that the U.S. Food & Drug Administration has accepted for filing the New Drug Application ("NDA") submitted on November 21, 2014 for its investigational drug, MorphaBond ER, an extended-release (ER), abuse-deterrent formulation of morphine.

10 Feb 2015

BPC opens new plasma collection center in Jacksonville, North Carolina

Biotest Pharmaceuticals Corporation, a leading developer of immunology biotherapeutic products, is pleased to announce that it has opened a new plasma collection center. The state-of-the-art, 15,000 square foot facility located at 113 Yopp Road, Jacksonville, North Carolina, is BPC's second plasma center in Jacksonville, and officially opened its doors for business on February 3, 2015.

9 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

Gramicidin-Based Fluorescence Assay can help predict drug toxicity

Sometimes, toxic side effects aren't discovered until fairly late in the drug development process, when substantial amounts of time and money have already been invested in clinical trials.

9 Feb 2015

Researchers study epidemiology of Ebola Virus Disease to prevent future disease outbreaks

Now, researchers from Arizona State University and Georgia State University are trying to better understand the epidemiology and control of Ebola Virus Disease in order to alleviate suffering and prevent future disease outbreaks from reaching the catastrophic proportions of the current crisis.

9 Feb 2015

Overview of chlamydia trachomatis infections

RnRMarketResearch.com adds "Chlamydia Trachomatis Infections - Pipeline Review, H1 2015" research to its store.

8 Feb 2015

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

At the "Symposium on the Application of Genetic Testing in Individualized Diagnosis and Treatment of Tumor" recently held in Tianjin, the research team led by Professor Hao Jihui of the Pancreas Oncology Department of Tianjin Medical University Cancer Hospital announced that they had achieved a major breakthrough in the field of nano-carrier drugs for pancreatic cancer.

6 Feb 2015

G1 Therapeutics receives $33 million in Series B funding to develop effective treatments for cancer

An RTP-based pharmaceutical company with roots at the University of North Carolina at Chapel Hill has received $33 million in Series B venture capital funding to develop more effective and less toxic methods to treat patients with cancer.

6 Feb 2015

TrialReach raises $13.5M in Series B financing round

TrialReach, the world's largest provider of clinical trial information, today announced it has raised a $13.5M Series B financing round led by Smedvig Capital with participation from existing investors Amadeus Capital Partners and Octopus Investments. With one of the biggest digital health rounds ever raised in the United Kingdom, TrialReach plans to use the funds to support the growth of its clinical trial platform and expansion into the U.S..

6 Feb 2015

Pharmaceuticals News and Research

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

Cumberland initiates clinical development of Boxaban (ifetroban) oral capsule for AERD treatment

First human clinical study of ChromaDex's NIAGEN nicotinamide riboside meets primary endpoint

IU School of Medicine launches Industry Collaboration Portal

UM one step closer to developing potential drug for treating brain cancer

SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies

Isis receives $5 million from Biogen Idec to develop drugs for neurological disorders

University of Tokyo researchers reveal how TLR9 binds to pathogen DNA

Researchers identify axitinib as promising candidate to treat drug-resistant leukaemia

Researchers discover inherited genetic variations associated with treatment-related hearing loss

Combination therapies may overcome resistance to targeted cancer drugs

FDA accepts NDA filing for Inspirion Delivery Technologies' investigational drug, MorphaBond ER

BPC opens new plasma collection center in Jacksonville, North Carolina

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Gramicidin-Based Fluorescence Assay can help predict drug toxicity

Researchers study epidemiology of Ebola Virus Disease to prevent future disease outbreaks

Overview of chlamydia trachomatis infections

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

G1 Therapeutics receives $33 million in Series B funding to develop effective treatments for cancer

TrialReach raises $13.5M in Series B financing round

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence